Document:

​

Exhibit 10.1
​
AMENDMENT TO SURETY BOND BACKSTOP AGREEMENT
​
This AMENDMENT TO SURETY BOND BACKSTOP AGREEMENT (this “Amendment”) is entered into as of July 18 , 2022 (the “Effective Date”), to the Surety Bond Backstop Agreement effective February 14, 2022 (the “Agreement”), entered into by and among CytoDyn Inc., a Delaware corporation (“CytoDyn”), David Fairbank Welch, both individually and in his capacity as trustee of the David F. and Heidi A. Welch Revocable Trust, Heidi A. Welch, both individually and in her capacity as trustee of the David F. and Heidi A. Welch Revocable Trust, and LRFA, LLC, a Delaware limited liability company (“LRFA” and, together with David F. Welch and Heidi A. Welch, each an “Indemnitor” and collectively the “Indemnitors”). 4-Good Ventures LLC (“4-Good”), is a party to this Amendment as it relates to Sections 3 and 4 below. CytoDyn, Indemnitors and 4-Good are collectively referred to herein as the “Parties” or each, individually, as a “Party”.
​
RECITALS
​
WHEREAS the Indemnitors and 4-Good previously entered into an Agreement and Waiver dated June 23, 2022, relating to the Make-Whole Warrant, on the express understanding that the Agreement would subsequently be amended to reflect the terms specified below; and
​
WHEREAS the Parties wish to amend the Agreement, as well as the Initial Warrant and the Make-Whole Warrant (together, the “Warrants”).
​
NOW, THEREFORE, in consideration of the consideration set forth in this Amendment and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree to amend the Agreement and the Warrants as specified below.
​
	1.	Defined Terms. Terms used in this Amendment without definition shall have the meanings ascribed to them in the Agreement or the Warrants, as applicable.

​
	2.	Waiver of Reservation of Shares. The Parties, other than CytoDyn, waive the requirement of Section 2 of the Make-Whole Warrant relating to the reservation of shares underlying the Make-Whole Warrant until such time as an amendment to CytoDyn’s Certificate of Incorporation increasing the number of shares of Common Stock authorized for issuance by 350,000,000 shares (the “Certificate Amendment”) has been accepted for filing by the Delaware Secretary of State; provided that CytoDyn submits the Certificate Amendment to a vote of its stockholders no later than October 14, 2022, and, if the Certificate of Amendment receives the requisite approval of its

Page 1 – Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

​

stockholders, to submit the Certificate Amendment for filing with the Delaware Secretary of State promptly thereafter.
​
	3.	Extension of Term of Surety Bond Indemnity. The deadline for CytoDyn to post sufficient collateral to Surety in support of the Surety Bond and to obtain the release from Surety of the Surety Bond Indemnity shall be extended until November 15, 2022.

​
	4.	Amendments to Warrants. CytoDyn hereby amends the Warrants to provide as follows:

​
		(a)	The Exercise Price of all 30 million shares covered by the Warrants shall be $0.20 per share; and

​
		(b)	The Make-Whole Warrant covering 15 million shares will be exercisable in full beginning on the Effective Date through 5:00 p.m., Pacific Time, on the date that is five years following the date of the Make-Whole Warrant.

​
	5.	Registration of Warrant Shares. Section 2(b) of the Agreement is amended to read in full as follows:

​
“CytoDyn shall use its commercially reasonable efforts to file, no later than December 31, 2022, a Registration Statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) that is intended to register for resale the shares underlying the Warrants; provided, however, that in the event that CytoDyn is prevented from filing a registration statement, as a result of outstanding comments from the SEC, or because in the good faith judgment of the Board of Directors it would be materially detrimental to CytoDyn and its stockholders for such registration statement to either become effective or remain effective, because such action would (i) require premature disclosure of material information that CytoDyn has a bona fide business purpose for preserving as confidential; or (ii) render CytoDyn unable to comply with requirements under the federal securities laws, then CytoDyn shall have the right to defer taking action with respect to such S-3 filing for a period of not more than 60 days.”
​
	6.	Release of Surety Bond Indemnity. Upon the exercise of the Warrants in full by 4-Good, CytoDyn will take all reasonable steps promptly thereafter to cause the Surety to reduce the amount of the Surety Bond Indemnity for which the Indemnitors are liable, if any, by an amount, and to release collateral, if any, posted by the Indemnitors with a value, equal to the proceeds of the exercise of the Warrants.

​
	7.	General.

​
		(a)	Captions. Any captions for the sections of this Amendment are for convenience only and do not control or affect the meaning or construction of any of the provisions of this Amendment.

​
		(b)	Severability. If any term, condition, or provision of this Amendment, or any other document or instrument referred to in this Amendment, is held invalid for any

​

Page 2 – Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

​

reason, such offending term, condition, or provision shall be stricken therefrom, and the remainder of this Amendment shall not be affected thereby.
​
		(c)	Negotiated Agreement. This Amendment is a negotiated agreement. In the event of any ambiguity in this Amendment, such ambiguity shall not be subject to a rule of contract interpretation that would cause the ambiguity to be construed against any of the parties to this Amendment.

​
		(d)	Entire Agreement. Except as amended by this Amendment, all other provisions of the Agreement remain in full force and effect.

​
		(e)	Applicable Law. This Amendment shall be governed by and construed under the laws of the State of Washington, without regard to principles of conflicts of law.

​
​
​

Page 3 – Amendment to Surety Bond Backstop Agreement – CytoDyn – Welch

​

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date.
​
	CYTODYN:
	​
	INDEMNITORS:

	​
	​
	​
	​

	​
	​
	​
	​

	By:
	
	       
	

	Name: Antonio Migliarese
Title: CFO
​
	​
	David Fairbank Welch, both individually and
in his capacity as trustee of the David F. and
Heidi A. Welch Revocable Trust,

	4-Good Ventures, LLC, a Delaware
limited liability company
	​
	​
	​

	​
	​
	​
	

	By:
	
	​
	Heidi A. Welch, both individually and in her
capacity as trustee of the David F. and Heidi
A. Welch Revocable Trust

	Name: David F. Welch
Title:    President
	​
	​

	​
	​
	​

	​
	​
	LRFA LLC, a Delaware limited liability
company

	​
	​
	​

	​
	​
	​
	By:
	

	​
	​
	​
	Name: David F. Welch
Title:    President

​

Page 4 – Amendment to Surety Bond Backstop Agreement – CytoDyn – WelchExhibit 10.1

 

AMENDMENT NO.2 TO SECURED PROMISSORY NOTE NO.1

 

This Amendment No. 2 to the
Secured Promissory Note No. 1 (the “Amendment ”), is made as of July 19, 2022 is by VIA Motors International, Inc.,
(the “Borrower”). Capitalized terms used but not defined herein shall have the respective meanings given to them in
the Promissory Note (defined below).

 

WHEREAS,
the Borrower issued a certain Secured Promissory Note No. 1 dated May 20, 2022, as amended on June 17, 2022 (“Promissory Note”)
to Ideanomics Inc., (“Lender”) promising to repay the loan amount of $7,281,889.00 advanced
by the Lender.

 

WHEREAS, the Borrower wishes
to borrow, and the Lender wishes to advance, an additional amount of US$ 1,800,000.00 on the terms and conditions set forth in the Promissory
Note.

 

WHEREAS, the Borrower desires to amend the Promissory Note
as provided herein.

 

NOW, THEREFORE, in consideration
of the mutual covenants herein contained and other good and valuable consideration, the mutual receipt and legal sufficiency of which
are hereby acknowledged, the Parties, intending to be legally bound, mutually agree as follows:

 

	1.	Notwithstanding anything to the contrary in the Promissory Note, effective as of the date hereof:

 

		a.	the
principal sum payable under the Promissory Note shall be NINE MILLION EIGHTY-ONE THOUSAND EIGHT HUNDRED EIGHTY-NINE Dollars (US$9,081,889.00).
	 	 	 
		b.	Simple
interest on (i) US$ 2,181,889shall accrue from May 20, 2022; (ii) US$ 5,100,000 shall accrue from June 17, 2022; and (iii) US$ 1,800,000.00
shall accrue from the date hereof, in each case, till the Maturity Date at the rate of four percent (4%) per annum (such principal and
interest together and all other amounts due and owing under the Promissory Note, the “Obligations”).

 

	2.	Except to the extent herein expressly modified by the foregoing provisions of this
Amendment, the Promissory Note is hereby ratified and confirmed in all respects.
	 	 
	3.	This Amendment may be executed by electronic signatures and in any number of counterparts with the
           same effect as if all signatory parties had signed the same document. All counterparts shall be construed together and shall
           constitute one and the same instrument.

 

[signature page follows]

 

     

     

    

 

IN WITNESS WHEREOF, each of the parties hereto has caused this Amendment
to be duly executed and delivered in its name and on its behalf, all as of the day and year first above written.

 

	 	VIA MOTORS INTERNATIONAL, INC., a Delaware corporation
	 	 
	 	By:	/s/  Robert C. Purcell                 
	 	Name: Robert C. Purcell
	 	Title: CEO

 

	Acknowledged by:	 
	 	 
	IDEANOMICS, INC., a Nevada corporation	 
	 	 
	By:	/s/  Alf Poor                    	 
	Name: Alf Poor	 
	Title: Authorized SignatoryExhibit
10.1

 

Abri
SPAC I, Inc.

40
Main Street, #1009

Newark,
DE 19711

9663
Santa Monica Blvd., No. 1091

Beverly Hills, CA 90210

 

July
22, 2022

 

VIA
OVERNIGHT DELIVERY AND EMAIL

 

Apifiny
Group Inc.

1675
Broadway, 35th Floor New York, NY 10019

Attention:
Haohan Xu, Chief Executive Officer

haohan@apifiny.com

 

Re:
Termination of Merger Agreement

 

Ladies
and Gentlemen:

 

Pursuant
to Section 10.1(d) of that certain Merger Agreement, dated as of January 27, 2022 (as amended, modified or supplemented from time to
time, the “Merger Agreement”), by and among Apifiny Group Inc. (the “Company”), Abri SPAC I, Inc. (“Parent”),
Abri Merger Sub, Inc., and Abri Ventures I, LLC, as indemnified party representative (each individually referred as a “Party”
and collectively, the “Parties”), the Merger Agreement may be terminated at any time by mutual written consent of the Company
and Parent duly authorized by each of their respective boards of directors. Capitalized terms used but not defined herein have the meanings
ascribed to them in the Merger Agreement.

 

Notwithstanding
anything to the contrary contained in the Merger Agreement, the Parties agree as follows:

 

1.
Acting pursuant to Section 10.1(d) of the Merger Agreement and with due authorization from their respective boards of directors, the
Parent and the Company agree to terminate the Merger Agreement, effective as of 11:59 p.m. Eastern Daylight Time on the date first written
above (“Termination Date”), including provisions of the Merger Agreement which by their terms would otherwise have survived
the termination of the Merger Agreement; provided, however, that the provisions of Section 8.3, Article XI, and Article XII (other than
Section 12.4) of the Merger Agreement shall survive the termination of the Merger Agreement and continue in effect.

 

2.
The Parties agree to terminate the Additional Agreements as of Termination Date without further action on the part of the parties thereto,
including provisions in the Additional Agreements which by their terms would otherwise have survived the termination; provided, that
the Assurance Escrow Agreement shall terminate in accordance with its terms upon the release to TipTop of the Escrow Shares in the manner
contemplated by paragraph 6 below.

 

3.
No Party shall issue a press release or similar formal public statement relating to the Merger Agreement or the termination of the Merger
Agreement (the “Public Announcement”) without all Parties’ prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed. The foregoing does not apply to disclosures by a Party (a) for which the requirement hereunder to obtain
the other Party’s prior written consent is prohibited by law or (b) to the extent required by law or pursuant to the rules or regulations
of any securities exchange and in response to a request for information from an Authority, or as required as part of a periodic regulatory
filing. The Parties agree that the attached press release and Current Report on Form 8K shall constitute the Public Announcement.

 

     

     

    

 

4.
No Party shall, and shall not cause any officer or Affiliate to, disparage any other Party in any manner whatsoever whether in writing,
orally or otherwise in any media. Without limitation, each Party shall not engage in any vilification of any Party, and each Party shall
refrain from making any false, negative, critical or disparaging statements concerning any other Party, including those pertaining to
management style, methods of doing business, the quality of products and services, role in the community, or treatment of employees.
Notwithstanding the foregoing, and for the purpose of clarification, no Party shall be deemed to be in breach of this paragraph 4 (a)
based on or as a result of such Party’s making of any disclosure or provision of information to the extent (i) required by law
or pursuant to the rules or regulations of any securities exchange or (ii) in response to a request for information from an Authority
or (b) based on or as a result of such Party’s making of any statement or claim, or such Party’s provision of information,
in or pursuant to any Action to the extent such statement or claim is made, or such information is provided, in furtherance of or with
respect to any right, claim, or matter not waived, released or discharged pursuant to paragraph 7 hereof.

 

5.
No Party shall make, share, publish or communicate to any person or entity, in any public or private forum or through any medium any
information whatsoever, directly or indirectly, about another Party, the Merger Agreement, the termination of the Merger Agreement or
related transactions or matters obtained or derived in connection with the Merger Agreement or its termination, without the affected
Party’s express written consent. Notwithstanding the foregoing, and for the purpose of clarification, no Party shall be deemed
to be in breach of this paragraph 5 (a) based on or as a result of such Party’s making of any disclosure or provision of information
to the extent (i) required by law or pursuant to the rules or regulations of any securities exchange or (ii) in response to a request
for information from an Authority or (b) based on or as a result of such Party’s making of any statement or claim, or such Party’s
provision of information, in or pursuant to any Action to the extent such statement or claim is made, or such information is provided,
in furtherance of or with respect to any right, claim, or matter not waived, released or discharged pursuant to paragraph 7 hereof.

 

6.
Upon the issuance of the Public Announcement, the Company will send Continental Stock Transfer & Trust Company (“Escrow Agent”)
the Termination Notice as contemplated by, and in compliance with, Section 4(c) of the Assurance Escrow Agreement, dated February 3,
2022, (the “Assurance Escrow Agreement”) advising the Escrow Agent of the termination of the Merger Agreement and instructing
the Escrow Agent to release and deliver to TipTop Century Limited ("TipTop") the Escrow Shares (as defined in the Assurance
Escrow Agreement), a copy of which shall be provided by the Company to the Sponsor and TipTop simultaneously, and shall include a copy
of the Public Announcement. Parent agrees that it will not object to the release and delivery to TipTop of the Escrow Shares pursuant
to the Termination Notice. In the event of any inconsistency between the terms of this paragraph 6 and the Assurance Escrow Agreement,
the terms of the Assurance Escrow Agreement shall govern.

 

7.
To the fullest extent permitted by law, each Party irrevocably, unconditionally and completely waives, and releases and forever discharges
any other Party (and any shareholder, director, officer, employee, Affiliate, agent, consultant or representative of such Party) from,
all claims, damages, costs and expenses, whether known or unknown or due or owing in the past, present or future, arising from any matter
concerning, based upon, in connection with, or relating to, the Merger Agreement or the Additional Agreements, or the termination thereof
or of the transactions contemplated thereby; provided, that (a) for the purpose of clarification, the foregoing waiver, release and discharge
shall not apply to or otherwise affect the rights of any Party under Section 8.3, Article XI and Article XII (other than Section 12.4)
of the Merger Agreement or the Assurance Escrow Agreement to the extent (and for so long as) such provisions survive the termination
of such agreements pursuant to this letter agreement and (b) nothing in this letter agreement shall relieve any Party for such Party’s
willful breach of its covenants or agreements in the Merger Agreement or its intentional fraud or willful misconduct prior to the termination
of the Merger Agreement. Each Party confirms that it has not assigned to any third party any claims that such Party has waived, released
or discharged pursuant to this paragraph 7. 

 

    2

     

    

 

8.
This letter agreement will be governed by, and construed in accordance with, the Laws of the State of Delaware. If any Action is brought
for the enforcement of this letter agreement, or in the event of any dispute, breach or default in connection with any of the provisions
of this letter agreement, the prevailing party in such Action shall be entitled to recover from the non-prevailing party or non-prevailing
parties in such Action reasonable attorneys' fees and other costs incurred in that action or proceeding in addition to any other relief
to which the prevailing party may be entitled. This letter agreement may be executed and delivered (including by facsimile or portable
document format (.pdf transmission)) in one or more counterparts, and by the different Parties in separate counterparts, each of which
when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

Kindly
signify your conformity by signing this letter-agreement in the space provided below. Very truly yours,

ABRI
SPAC I, INC.

 

	Very truly yours,	 
	 	 
	ABRI
    SPAC I, INC.	 
	 	 	 
	By:
	/s/Jeffrey
    Tirman	 
	Name: 	Jeffrey Tirman	 
	Title: 	Chief Executive Officer	 

 

	ABRI
                                            MERGER SUB, INC.
	 
	 	 	 
	By:
	/s/Jeffrey
    Tirman	 
	Name: 	Jeffrey Tirman	 
	Title: 	President
	 

 

	ABRI
    VENTURES I, LLC
	 	 	 
	By: 	/s/ Jeffrey
    Tirman	 
	Name: 
	Jeffrey Tirman	 
	Title: 	Managing Member	 

 

    3

     

    

 

	AGREED
    AND ACCEPTED:
	 
	APIFINY
    GROUP INC.
	 
	By:	/s/ Haohan Xu	 
	Name:  	Haohan Xu	 
	Title: 	Chief Executive Officer	 

 

With
a copy to:

 

Mayer
Brown LLP

1221
Avenue of the Americas

New
York, NY 10020

Attn:
Phyllis Korff, Esq., and Andrew Noreuil, Esq.

E-mail:
pkorff@mayerbrown.com; anoreuil@mayerbrown.com

 

Loeb
& Loeb LLP 345 Park Avenue

New
York, NY 10154 (212) 407-4000

Attn:
Mitchell S. Nussbaum, Esq., and Alex Weniger-Araujo, Esq.

Email:
mnussbaum@loeb.com; aweniger@loeb.com

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]